Oramed Pharmaceuticals (FRA:OJU1) Shares Outstanding (EOP): 40.93 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OJU1 Oramed Pharmaceuticals Inc FRA:OJU1
32 GF Score
Price €3.48
! 4 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals Shares Outstanding (EOP)?

Oramed Pharmaceuticals FRA:OJU1 -3.61% 32 Shares Outstanding (EOP) is 40.93 Mil as of Mar. 2026. GuruFocus rates FRA:OJU1 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Oramed Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 40.93 Mil.

Oramed Pharmaceuticals's quarterly shares outstanding increased from Dec. 2025 (39.28 Mil) to Mar. 2026 (40.93 Mil). It means Oramed Pharmaceuticals issued new shares from Dec. 2025 to Mar. 2026 .

Oramed Pharmaceuticals's annual shares outstanding declined from Dec. 2024 (39.92 Mil) to Dec. 2025 (39.28 Mil). It means Oramed Pharmaceuticals bought back shares from Dec. 2024 to Dec. 2025 .


Oramed Pharmaceuticals  (FRA:OJU1) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Oramed Pharmaceuticals Shares Outstanding (EOP) Related Terms


Oramed Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Shares Outstanding (EOP) Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.29 39.56 40.34 39.92 39.28

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.85 40.85 40.84 39.28 40.93

FRA:OJU1 vs CAMP, PYXS, ALEC: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Shares Outstanding (EOP) falls into.


FRA:OJU1
32GF Score
Oramed Pharmaceuticals Inc FRA:OJU1
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 40.93 Mil mean?
Oramed Pharmaceuticals (FRA:OJU1) has a Shares Outstanding (EOP) of 40.93 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' Shares Outstanding (EOP) too high?
Oramed Pharmaceuticals' current Shares Outstanding (EOP) is 40.93 Mil. Overall, Oramed Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' Shares Outstanding (EOP) compare to CAMP and PYXS?
Oramed Pharmaceuticals' Shares Outstanding (EOP) of 40.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current Shares Outstanding (EOP) is 40.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (FRA:OJU1) has a current Shares Outstanding (EOP) of 40.93 Mil. The current Shares Outstanding (EOP) is 40.93 Mil. Oramed Pharmaceuticals' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Oramed Pharmaceuticals (FRA:OJU1), the current Shares Outstanding (EOP) is 40.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
32GF Score

Get the complete analysis for FRA:OJU1

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price